ÌÇÐÄvlog´«Ã½

Retinoblastoma Treatment Market Analysis

The Retinoblastoma Treatment Market size is estimated at USD 1.85 billion in 2024, and is expected to reach USD 2.30 billion by 2029, growing at a CAGR of 4.45% during the forecast period (2024-2029).

The COVID-19 pandemic created a significant void in the availability and accessibility of treatment modalities and timely intervention for children with eye cancer. For instance, according to an article published by the Indian Journal of Ophthalmology, in September 2021, the COVID-19-related nationwide lockdown deprived retinoblastoma patients of optimal and timely management, leading to prolonged treatment interruptions. Thus, COVID-19 had an impact on the retinoblastoma treatment market. However, with the decreasing number of COVID-19 cases, the demand for ophthalmic treatment and surgeries increased. For instance, according to an article published by the American Academy of Ophthalmology in November 2021, patients began pouring in with advanced eye cancers in October 2021, and there was an alarming rise in patients that required enucleation. Further, according to the same source, more young children with advanced cases of retinoblastoma were observed in the hospitals in Philadelphia. Hence, with the declining COVID-19 cases, there was an increase in retinoblastoma treatments, thereby fueling market growth, and the same is expected over the forecast period.

Certain factors driving the market growth include remission and the chance of recurrence of retinoblastoma and increasing public awareness of retinoblastoma. For instance, according to an article published by Bone Report, in December 2021, recurrence of retinoblastoma usually occurs within the first few years after treatment. Despite complete tumor regression, delayed relapse of retinoblastoma can occur, predisposing patients to osteosarcoma as a second malignancy. Furthermore, according to an article published by the National Library of Medicine in June 2021, Kaplan-Meier's estimate of tumor recurrence at six months, one year, three years, and five years was 20%, 31%, 68%, and 73%, respectively in 2021. Thus, the remission and the chance of recurrence of retinoblastoma are expected to boost market growth.

Furthermore, every year, to raise awareness, the 2nd week of May is observed as "World Retinoblastoma Awareness Week" around the World. It is an opportunity to raise global awareness of retinoblastoma, a life-threatening eye cancer that is almost exclusively found in young children every year. Hence, rising awareness regarding diseases is projected to boost market growth over the forecast period.

However, the side effects of retinoblastoma surgery and the high cost of treatment in developing countries are likely to hinder market growth over the forecast period.

Retinoblastoma Treatment Market Trends

This section covers the major market trends shaping the Retinoblastoma Treatment Market according to our research experts:

Non-hereditary Retinoblastoma is Expected to hold a Significant Market Share Over the Forecast Period

Retinoblastoma Treatment Industry Segmentation

As per the scope of the report, Retinoblastoma is a rare type of eye cancer that usually develops in early childhood, typically before the age of 5. The most common symptom of retinoblastoma is a visible whiteness in the pupil, called a cat's eye reflex or leukocoria. 

The Retinoblastoma Treatment Market is Segmented by Treatment Type (Surgery, Radiation therapy, Laser therapy, Cryotherapy, Chemotherapy, and Bone Marrow Transplantation/Stem Cell Transplant), Type of Retinoblastoma (Non-hereditary Retinoblastoma, and Hereditary Retinoblastoma), Type of Staging (Intraocular Retinoblastoma, and Extraocular Retinoblastoma), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD million) for the above segments.